240 related articles for article (PubMed ID: 38246477)
21. Medications development: successes and challenges.
Vocci F; Ling W
Pharmacol Ther; 2005 Oct; 108(1):94-108. PubMed ID: 16083966
[TBL] [Abstract][Full Text] [Related]
22. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.
Grabowski J; Shearer J; Merrill J; Negus SS
Addict Behav; 2004 Sep; 29(7):1439-64. PubMed ID: 15345275
[TBL] [Abstract][Full Text] [Related]
23. The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.
Knudsen HK; Roman PM
J Stud Alcohol Drugs; 2014 May; 75(3):476-85. PubMed ID: 24766760
[TBL] [Abstract][Full Text] [Related]
24. Considerations in the Evaluation of Potential Efficacy of Medications for Alcohol and Drug Use Disorders: An Editorial.
Egli M; White DA; Acri JB
Int Rev Neurobiol; 2016; 126():1-14. PubMed ID: 27055609
[TBL] [Abstract][Full Text] [Related]
25. Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review.
Tardelli VS; Lago MPPD; Mendez M; Bisaga A; Fidalgo TM
Behav Res Ther; 2018 Dec; 111():57-63. PubMed ID: 30316027
[TBL] [Abstract][Full Text] [Related]
26. Substance Use Disorder.
Swimmer KR; Sandelich S
Emerg Med Clin North Am; 2024 Feb; 42(1):53-67. PubMed ID: 37977753
[TBL] [Abstract][Full Text] [Related]
27. Medications for substance use disorders (SUD): emerging approaches.
Butelman ER; Kreek MJ
Expert Opin Emerg Drugs; 2017 Dec; 22(4):301-315. PubMed ID: 29057665
[TBL] [Abstract][Full Text] [Related]
28. Advancing health care via artificial intelligence: From concept to clinic.
Sandeep Ganesh G; Kolusu AS; Prasad K; Samudrala PK; Nemmani KVS
Eur J Pharmacol; 2022 Nov; 934():175320. PubMed ID: 36220360
[TBL] [Abstract][Full Text] [Related]
29. AMCP Partnership Forum: Designing Benefits and Payment Models for Innovative High-Investment Medications.
J Manag Care Spec Pharm; 2019 Feb; 25(2):156-162. PubMed ID: 30698091
[TBL] [Abstract][Full Text] [Related]
30. NIDA Boosts Research and Development of Medical Devices for Substance use Disorder via the NIH Blueprint MedTech Initiative.
Kostov Y; Angelone L; Gutowski S; Koustova E
Subst Use Misuse; 2023; 58(5):735-738. PubMed ID: 36866964
[No Abstract] [Full Text] [Related]
31. IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
Yaden DB; Berghella AP; Hendricks PS; Yaden ME; Levine M; Rohde JS; Nayak S; Johnson MW; Garcia-Romeu A
Pharmacol Res; 2024 Jan; 199():106998. PubMed ID: 38029805
[TBL] [Abstract][Full Text] [Related]
32. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR; Theodore G
J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
[TBL] [Abstract][Full Text] [Related]
33. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
Janero DR
Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic treatments for drug and alcohol dependence.
Kranzler HR; Amin H; Modesto-Lowe V; Oncken C
Psychiatr Clin North Am; 1999 Jun; 22(2):401-23. PubMed ID: 10385941
[TBL] [Abstract][Full Text] [Related]
35. A Review on Deep Learning-driven Drug Discovery: Strategies, Tools and Applications.
Sumathi S; Suganya K; Swathi K; Sudha B; Poornima A; Varghese CA; Aswathy R
Curr Pharm Des; 2023 May; 29(13):1013-1025. PubMed ID: 37055908
[TBL] [Abstract][Full Text] [Related]
36. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
[TBL] [Abstract][Full Text] [Related]
37. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
Kollins SH
Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
[TBL] [Abstract][Full Text] [Related]
38. A Therapeutic Relational Agent for Reducing Problematic Substance Use (Woebot): Development and Usability Study.
Prochaska JJ; Vogel EA; Chieng A; Kendra M; Baiocchi M; Pajarito S; Robinson A
J Med Internet Res; 2021 Mar; 23(3):e24850. PubMed ID: 33755028
[TBL] [Abstract][Full Text] [Related]
39. Integrative Pharmacology in the Treatment of Substance Use Disorders.
Donlon J; Kumari P; Varghese SP; Bai M; Florentin OD; Frost ED; Banks J; Vadlapatla N; Kam O; Shad MU; Rahman S; Abulseoud OA; Stone TW; Koola MM
J Dual Diagn; 2024; 20(2):132-177. PubMed ID: 38117676
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
